Cryo-Cell International Inc. (CCEL)
NYSE: CCELHealth CareMisc Health and Biotechnology ServicesUSD
At close: Nov 20, 3:55 PM ET · Delayed 15 min
CCEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $33.46M
- Forward P/E
- 207.50
- EPS (TTM)
- -$0.24
- Dividend yield
- None
- Ex-dividend date
- May 21, 2025
- 52-week range
- 2.72 – 5.45
- Day range
- 4.15 – 4.20
- Volume / Avg
- 2.64K / 13.02K
- Beta
- —
- Shares outstanding
- 8.06M
52-week range
CCEL stock today
Cryo-Cell International (CCEL) closed at $4.15 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 2.64K shares changing hands, about 20% of the average daily volume. Shares are 23.9% below their 52-week high of $5.45, set on Oct 29, 2026 and 52.6% above the 52-week low of $2.72, in the middle of the past year's range.
CCEL is up 20.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.5%. Cryo-Cell International has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cryo-Cell International
Company profileCryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- CEO
- Mr. David I. Portnoy
- Headquarters
- Oldsmar, FL
- Employees
- 72
- IPO year
- 2022
- Website
- cryo-cell.com
Financial highlights
Full financialsIn fiscal 2025, Cryo-Cell International generated $31.6 million in revenue, down 1.3% from fiscal 2024, its first annual decline since 2021. Cryo-Cell International reported a net loss of $2.4 million, compared with net income of $402,095 a year earlier. Gross margin was 76.6% (up from 75.2%) and operating margin 1.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $31.57M | $31.99M | $31.34M | $30.34M | $28.88M |
| Growth | -1.31% | +2.05% | +3.32% | +5.03% | -7.26% |
| Net income | $-2.43M | $402.10K | $-9.52M | $2.77M | $2.08M |
| EPS (diluted) | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 |
Earnings
Earnings history- Last reported (Aug/2026)
- Oct 9, 2026
- EPS actual vs est.
- $0.16 vs —
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.15
- Ex-dividend date
- May 21, 2025
CCEL news
All CCEL newsCryo-Cell International peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MGRXMangoceuticals Inc. | 0.1236 | -7.55% | $2.75M | vs CCEL |
| NIVFNewGenIvf Group Limited Class A | 0.0269 | -23.14% | $80.77K | vs CCEL |
| PARKPark Dental Partners Inc. | 17.03 | -6.79% | $94.26M | vs CCEL |
| VMDViemed Healthcare Inc. | 8.52 | -1.05% | $322.85M | vs CCEL |
| AGLagilon health inc. | 90.24 | +0.83% | $1.52B | vs CCEL |
| PGNYProgyny Inc. | 35.71 | +0.73% | $2.63B | vs CCEL |
| SHCSotera Health Company | 15.91 | -1.85% | $4.54B | vs CCEL |
| DVADaVita Inc. | 161.03 | +3.00% | $10.13B | vs CCEL |
Indexes, lists and sector
Cryo-Cell International stock FAQ
What is Cryo-Cell International's stock price today?
CCEL last traded at $4.15 as of Nov 20, 3:55 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does Cryo-Cell International pay a dividend?
Yes. Cryo-Cell International pays $0.00 per share annually. The most recent dividend of $0.15 had an ex-dividend date of May 21, 2025.
Who is Cryo-Cell International's CEO?
Mr. David I. Portnoy is the chief executive officer of Cryo-Cell International Inc., which has about 72 employees.
What is the CCEL 52-week high?
The 52-week high for CCEL is $5.45 and the 52-week low is $2.72. The stock is currently 23.9% below its high.